TSE:4506Pharmaceuticals
Is Sumitomo Pharma (TSE:4506) Quietly Recasting Its Investment Story Around Regenerative Medicine And GEMTESA?
In early March 2026, Sumitomo Pharma secured conditional Japanese approval for AMCHePRY, the world’s first iPS cell-derived regenerative therapy for Parkinson’s disease patients whose symptoms are not adequately controlled by existing drugs, while also raising its full-year revenue and profit guidance, helped by stronger GEMTESA sales in North America and a weaker yen.
The company’s decision on the same day to prepare a shelf registration for potential new share issuance, alongside its...